Literature DB >> 10559200

Quantitative analysis of formyl peptide receptor coupling to g(i)alpha(1), g(i)alpha(2), and g(i)alpha(3).

K Wenzel-Seifert1, J M Arthur, H Y Liu, R Seifert.   

Abstract

The human formyl peptide receptor (FPR) is a prototypical G(i) protein-coupled receptor, but little is known about quantitative aspects of FPR-G(i) protein coupling. To address this issue, we fused the FPR to G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) and expressed the fusion proteins in Sf9 insect cells. Fusion of a receptor to Galpha ensures a defined 1:1 stoichiometry of the signaling partners. By analyzing high affinity agonist binding, the kinetics of agonist- and inverse agonist-regulated guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) binding and GTP hydrolysis and photolabeling of Galpha, we demonstrate highly efficient coupling of the FPR to fused G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) without cross-talk of the receptor to insect cell G proteins. The FPR displayed high constitutive activity when coupled to all three G(i)alpha isoforms. The K(d) values of high affinity agonist binding were approximately 100-fold lower than the EC(50) (concentration that gives half-maximal stimulation) values of agonist for GTPase activation. Based on the B(max) values of agonist saturation binding and ligand-regulated GTPgammaS binding, it was previously proposed that the FPR activates G proteins catalytically, i.e. one FPR activates several G(i) proteins. Analysis of agonist saturation binding, ligand-regulated GTPgammaS saturation binding and quantitative immunoblotting with membranes expressing FPR-G(i)alpha fusion proteins and nonfused FPR now reveals that FPR agonist binding greatly underestimates the actual FPR expression level. Our data show the following: (i) the FPR couples to G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) with similar efficiency; (ii) the FPR can exist in a state of low agonist affinity that couples efficiently to G proteins; and (iii) in contrast to the previously held view, the FPR appears to activate G(i) proteins linearly and not catalytically.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559200     DOI: 10.1074/jbc.274.47.33259

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Functional differences between human formyl peptide receptor isoforms 26, 98, and G6.

Authors:  Katharina Wenzel-Seifert; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-05       Impact factor: 3.000

2.  Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphates.

Authors:  Srividya Suryanarayana; Martin Göttle; Melanie Hübner; Andreas Gille; Tung-Chung Mou; Stephen R Sprang; Mark Richter; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2009-06-03       Impact factor: 4.030

3.  Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cells.

Authors:  Patrick Kleemann; Dan Papa; Sandy Vigil-Cruz; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-04       Impact factor: 3.000

Review 4.  Expression and signaling of formyl-peptide receptors in the brain.

Authors:  Fabio Cattaneo; Germano Guerra; Rosario Ammendola
Journal:  Neurochem Res       Date:  2010-11-02       Impact factor: 3.996

Review 5.  Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors.

Authors:  Dominik Alexander Bloes; Dorothee Kretschmer; Andreas Peschel
Journal:  Nat Rev Microbiol       Date:  2014-12-15       Impact factor: 60.633

Review 6.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

7.  Establishment of recombinant cannabinoid receptor assays and characterization of several natural and synthetic ligands.

Authors:  Sarah Geiger; Kathrin Nickl; Erich H Schneider; Roland Seifert; Jörg Heilmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-09       Impact factor: 3.000

8.  Role of the second and third extracellular loops of the histamine H(4) receptor in receptor activation.

Authors:  Irena Brunskole; Andrea Strasser; Roland Seifert; Armin Buschauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

Review 10.  Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Ye Zhou; Yingying Le; Xiuwu Bian; Ji Ming Wang
Journal:  Cancer Lett       Date:  2008-04-22       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.